Login / Signup

Appropriate use of triazolam in elderly patients considering a quantitative benefit-risk assessment based on the pharmacokinetic-pharmacodynamic modeling and simulation approach supported by real-world data.

Akira OkadaShoji SeraNaomi Nagai
Published in: BMC pharmacology & toxicology (2024)
Analyzing large-scale databases and existing research publications on PK/PD can practically contribute to optimizing triazolam drug therapy for the elderly in the daily clinical setting.
Keyphrases
  • risk assessment
  • big data
  • electronic health record
  • physical activity
  • human health
  • middle aged
  • high resolution
  • heavy metals
  • community dwelling
  • adverse drug
  • virtual reality
  • drug induced
  • data analysis